April 24, 2012; 78 (17) Special Articles
Evidence-based guideline update: NSAIDs and other complementary treatments for episodic migraine prevention in adults: [RETIRED]
Report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society
S. Holland, S.D. Silberstein, F. Freitag, D.W. Dodick, C. Argoff, E. Ashman
First published April 23, 2012, DOI: https://doi.org/10.1212/WNL.0b013e3182535d0c
S. Holland
From the Armstrong Atlantic State University (S.H.), Savannah, GA; Thomas Jefferson University (S.D.S.), Jefferson Headache Center, Philadelphia, PA; Comprehensive Headache Center (F.F.), Baylor University Headache Medicine Center, Dallas, TX; Mayo Clinic (D.D.), Scottsdale, AZ; New York University School of Medicine (C.A.), Albany; and Elmendorf Air Force Base (E.A.), AK.
S.D. Silberstein
From the Armstrong Atlantic State University (S.H.), Savannah, GA; Thomas Jefferson University (S.D.S.), Jefferson Headache Center, Philadelphia, PA; Comprehensive Headache Center (F.F.), Baylor University Headache Medicine Center, Dallas, TX; Mayo Clinic (D.D.), Scottsdale, AZ; New York University School of Medicine (C.A.), Albany; and Elmendorf Air Force Base (E.A.), AK.
F. Freitag
From the Armstrong Atlantic State University (S.H.), Savannah, GA; Thomas Jefferson University (S.D.S.), Jefferson Headache Center, Philadelphia, PA; Comprehensive Headache Center (F.F.), Baylor University Headache Medicine Center, Dallas, TX; Mayo Clinic (D.D.), Scottsdale, AZ; New York University School of Medicine (C.A.), Albany; and Elmendorf Air Force Base (E.A.), AK.
D.W. Dodick
From the Armstrong Atlantic State University (S.H.), Savannah, GA; Thomas Jefferson University (S.D.S.), Jefferson Headache Center, Philadelphia, PA; Comprehensive Headache Center (F.F.), Baylor University Headache Medicine Center, Dallas, TX; Mayo Clinic (D.D.), Scottsdale, AZ; New York University School of Medicine (C.A.), Albany; and Elmendorf Air Force Base (E.A.), AK.
C. Argoff
From the Armstrong Atlantic State University (S.H.), Savannah, GA; Thomas Jefferson University (S.D.S.), Jefferson Headache Center, Philadelphia, PA; Comprehensive Headache Center (F.F.), Baylor University Headache Medicine Center, Dallas, TX; Mayo Clinic (D.D.), Scottsdale, AZ; New York University School of Medicine (C.A.), Albany; and Elmendorf Air Force Base (E.A.), AK.
E. Ashman
From the Armstrong Atlantic State University (S.H.), Savannah, GA; Thomas Jefferson University (S.D.S.), Jefferson Headache Center, Philadelphia, PA; Comprehensive Headache Center (F.F.), Baylor University Headache Medicine Center, Dallas, TX; Mayo Clinic (D.D.), Scottsdale, AZ; New York University School of Medicine (C.A.), Albany; and Elmendorf Air Force Base (E.A.), AK.
Evidence-based guideline update: NSAIDs and other complementary treatments for episodic migraine prevention in adults: [RETIRED]
Report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society
S. Holland, S.D. Silberstein, F. Freitag, D.W. Dodick, C. Argoff, E. Ashman
Neurology Apr 2012, 78 (17) 1346-1353; DOI: 10.1212/WNL.0b013e3182535d0c
Citation Manager Formats
Make Comment
See Comments
Disputes & Debates: Rapid online correspondence
- Response to Dr. Mauskopf
- Starr Holland, Armstrong Atlantic State University, Savannah, GAguidelines@aan.com
- Stephen D. Silberstein, Philadelphia, PA; Frederick Freitag, Dallas, TX; David W. Dodick, Scottsdale, AZ; Charles Argoff, Albany, NY
Submitted August 28, 2012 - Safety of Petasites (butterbur)
- Alexander Mauskop, Director, New York Headache Centerdrmauskop@nyheadache.com
- New York, NY
Submitted July 25, 2012
NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.
- Stay timely. Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- 200 words maximum.
- 5 references maximum. Reference 1 must be the article on which you are commenting.
- 5 authors maximum. Exception: replies can include all original authors of the article.
- Submitted comments are subject to editing and editor review prior to posting.